Skip to main content

Table 3 Association between csDMARDs and clinical response (∆BASDAI ≥ 2.0) or remission (BASDAI < 2 and CRP ≤ 5 mg/L) at 1 year, stratified for body mass index

From: Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

  BMI ≤ 25 (n = 60; 42%) BMI > 25 (n = 81; 58%)
OR 95% CI OR 95% CI
Clinical response
 Any csDMARD 1.10 0.33–3.58 7.86 2.39–25.78*
 MTX [± SSZ] 1.04 0.25–4.25 9.82 2.13–45.20*
 SSZ 1.18 0.25–5.63 6.86 1.85–25.40*
Remission
 Any csDMARD 0.76 0.20–2.86 4.84 1.09–21.36*
 MTX [± SSZ] 0.60 0.11–3.18 5.56 0.84–36.52
 SSZ 0.99 0.17–5.64 4.35 0.77–24.54
  1. The adjusted multivariable logistic regression analysis included 141 patients. Two different models are presented for the following outcomes: clinical response and remission. Odds ratio (OR) and 95% confidence interval (CI) were calculated. All models were adjusted for age, gender, disease duration, HLA-B27, baseline BASDAI and CRP. *p value < 0.05 was considered statistically significant. BMI body mass index, HLA-B27 human leucocyte antigen B27, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, MTX methotrexate, SSZ sulfasalazine